A Trial Investigating the Safety, Tolerability, Availability and Distribution in the Body of Once-weekly Long-acting Growth Hormone Compared to Once Daily Norditropin NordiFlex® in Adults With Growth Hormone Deficiency

This study has been completed.
Information provided by (Responsible Party):
Novo Nordisk A/S
ClinicalTrials.gov Identifier:
First received: October 11, 2012
Last updated: November 26, 2013
Last verified: November 2013
This trial is conducted in Europe. The aim of the trial is to investigate the safety, tolerability, availability and distribution in the body of once-weekly long-acting growth hormone (NNC0195-0092) compared to once daily Norditropin NordiFlex® in adults with growth hormone deficiency (GHD).

Condition Intervention Phase
Growth Hormone Disorder
Adult Growth Hormone Deficiency
Drug: NNC0195-0092
Drug: Norditropin NordiFlex®
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Randomised, Open-labelled, Active-controlled, Multiple Dose, Dose Escalating, Sequential Dose Group Trial Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Once-weekly Long-acting Growth Hormone (NNC0195-0092) Compared to Once-daily Norditropin NordiFlex® in Adults With Growth Hormone Deficiency

Resource links provided by NLM:

Further study details as provided by Novo Nordisk A/S:

Primary Outcome Measures:
  • Incidence of adverse events (AEs) [ Time Frame: From first administration of trial product and up until Day 49 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • NNC0195-0092 only: Area under the curve, AUC (0-168h) [ Time Frame: From 0 to 168 hours ] [ Designated as safety issue: No ]
  • Norditropin NordiFlex® only: AUC (0-24h) [ Time Frame: From 0 to 24 hours ] [ Designated as safety issue: No ]
  • NNC0195-0092, first dose administration only: AUC (0-168h) [ Time Frame: From 0 to 168 hours ] [ Designated as safety issue: No ]
  • Norditropin NordiFlex®, first dose administration only: AUC (0-24h) [ Time Frame: From 0 to 24 hours ] [ Designated as safety issue: No ]
  • NNC0195-0092: Maximum serum concentration (Cmax) [ Time Frame: From 0 to 168 hours ] [ Designated as safety issue: No ]
  • Norditropin NordiFlex®: Cmax [ Time Frame: From 0 to 24 hours ] [ Designated as safety issue: No ]
  • Insulin-like growth factor I (IGF-I): AUC (0-168h) [ Time Frame: From 0 to 168 hours ] [ Designated as safety issue: No ]
  • IGF-I: Cmax [ Time Frame: From 0 to 168 hours ] [ Designated as safety issue: No ]
  • Insulin-like growth factor binding protein-3 (IGFBP-3): AUC IGFBP-3(0-168h) [ Time Frame: From 0 to 168 hours ] [ Designated as safety issue: No ]
  • IGFBP-3: Cmax [ Time Frame: From 0 to 168 hours ] [ Designated as safety issue: No ]

Enrollment: 35
Study Start Date: October 2012
Study Completion Date: November 2013
Primary Completion Date: November 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: NNC0195-0092 Drug: NNC0195-0092
Subcutaneous (s.c., under the skin) administration once weekly (Days 1, 8, 15 and 22) of 4 different doses of NNC0195-0092 in an escalating order
Active Comparator: Norditropin NordiFlex® Drug: Norditropin NordiFlex®
Subcutaneous (s.c., under the skin) administration daily for 28 days. The daily dosing will be the same as the pre-trial daily dose of human growth hormone (hGH) taken by the adult with growth hormone deficiency


Ages Eligible for Study:   20 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Adults with GHD as defined in the consensus guidelines for the diagnosis and treatment of adults with GHD
  • Stable human growth hormone (hGH) replacement therapy for at least 3 months

Exclusion Criteria:

  • Participation in another clinical trial within 3 months or receipt of any investigational medicinal product within 3 months prior to randomisation
  • Active malignant disease or malignant disease within the last 5 years with exception of fully treated local basal cell carcinoma or carcinoma in situ of cervix
  • Proliferative retinopathy judged by retina-photo within the last year - only with concomitant diabetes
  • Heart insufficiency, New York Heart Association (NYHA) class above 2
  • Adults with GHD with poorly controlled diabetes mellitus with a glycosylated haemoglobin (HbA1c) 64 mmol/mol (8.0%) and/or insulin treatment
  • Stable pituitary replacement therapy for less than 3 months
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01706783

København Ø, Denmark, 2100
Stockholm, Sweden, 141 86
Sponsors and Collaborators
Novo Nordisk A/S
Study Director: Lene Finnerup Nielsen Novo Nordisk A/S
  More Information

Additional Information:
Responsible Party: Novo Nordisk A/S
ClinicalTrials.gov Identifier: NCT01706783     History of Changes
Other Study ID Numbers: NN8640-3947  2011-005484-24  U1111-1125-7331 
Study First Received: October 11, 2012
Last Updated: November 26, 2013
Health Authority: Denmark: Danish Medicines Agency
Sweden: Medical Products Agency

Additional relevant MeSH terms:
Dwarfism, Pituitary
Endocrine System Diseases
Bone Diseases
Bone Diseases, Developmental
Bone Diseases, Endocrine
Brain Diseases
Central Nervous System Diseases
Hypothalamic Diseases
Musculoskeletal Diseases
Nervous System Diseases
Pituitary Diseases
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on May 26, 2016